Ken Griffin Adial Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.03 - $46.0 $7,951 - $12.2 Million	265,062 New	265,062 $93,000
Q3 2021 Nov 15, 2021	SELL	$57.75 - $116.75 $1.17 Million - $2.36 Million	-20,198 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$50.5 - $78.25 $2.73 Million - $4.23 Million	-54,093 Reduced 72.81%	20,198 $0
Q1 2021 May 17, 2021	SELL	$43.25 - $79.75 $115,910 - $213,730	-2,680 Reduced 3.48%	74,291 $180,000
Q4 2020 Feb 16, 2021	BUY	$42.25 - $58.25 $3.25 Million - $4.48 Million	76,971 New	76,971 $131,000
Q2 2019 Aug 14, 2019	SELL	N/A	-26,492 Closed	0 $0
Q1 2019 May 15, 2019	BUY	N/A	26,492 New	26,492 $0

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $26.6M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.